Michael Gelband’s Arcturus Therapeutics ARCT Stock Holding History

Michael Gelband’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-56,054	Closed	-$729K	–	1515
2025 Q2	$729K	Buy	56,054 +1,140	+2%	+$13.5K	0.01%	1051
2025 Q1	$582K	Buy	+54,914	New	+$872K	0.01%	1079
2024 Q1	–	Sell	-9,499	Closed	-$300K	–	1474
2023 Q4	$300K	Sell	9,499 -13,538	-59%	-$322K	﹤0.01%	1183
2023 Q3	$589K	Buy	23,037 +1,861	+9%	+$57.3K	0.01%	1180
2023 Q2	$607K	Sell	21,176 -8,988	-30%	-$245K	﹤0.01%	1286
2023 Q1	$723K	Buy	30,164 +348	+1%	+$6.24K	0.01%	1244
2022 Q4	$506K	Sell	29,816 -17,736	-37%	-$309K	0.01%	1170
2022 Q3	$705K	Buy	+47,552	New	+$798K	0.01%	1244
2021 Q4	–	Sell	-21,937	Closed	-$1.05M	–	2144
2021 Q3	$1.05M	Buy	+21,937	New	+$983K	0.01%	1000
2021 Q1	–	Sell	-23,302	Closed	-$1.01M	–	2098
2020 Q4	$1.01M	Sell	23,302 -13,753	-37%	-$931K	0.01%	853
2020 Q3	$1.59M	Buy	+37,055	New	+$1.84M	0.03%	479
2020 Q1	–	Sell	-11,135	Closed	-$121K	–	1068
2019 Q4	$121K	Buy	+11,135	New	+$117K	﹤0.01%	1411

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Michael Gelband's ARCT Position: Q3 2025 in Review

Michael Gelband sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 56,054 shares — an estimated $729K sold.

Michael Gelband first reported a position in ARCT in Q4 2019 and held it in 12 quarters. The position peaked at $1.59M in Q3 2020. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

Michael Gelband reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
Michael Gelband sold 56,054 Arcturus Therapeutics shares in Q3 2025, an estimated $729K.
Michael Gelband first reported a position in Arcturus Therapeutics in Q4 2019 and held it in 12 quarters.
Michael Gelband's Arcturus Therapeutics position peaked at $1.59M in Q3 2020.
136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.